Concentra
Delivers workplace injury care and employer health services through centers, worksites, and telemedicine.
Something off on this page? Send us feedback.
Profile
Provides workers' compensation care, physical rehabilitation, workforce screening, testing, and preventive services through U.S. occupational health centers, employer-site clinics, and telemedicine. Revenue is concentrated in the center network, and demand depends on employment activity, workplace injuries, employer relationships, and state reimbursement rules.
Provides occupational health care through stand-alone centers, employer-site clinics, and complementary businesses spanning telemedicine, pharmacy, and substance-testing administration. Core services cover workplace injury treatment and physical rehabilitation, plus employer-paid physicals, drug and alcohol screening, clinical testing, vaccinations, and preventive care. Limited consumer urgent care rounds out the mix.
Runs a national U.S. network that combines local clinical delivery with standardized workflows, employer account tools, and virtual access. Occupational health centers generate most revenue, while onsite clinics serve medium and large employers at their workplaces; all operations are combined in one reportable segment.
Demand follows employment, hiring, employee turnover, and workplace injury volumes. Workers' compensation reimbursement is governed largely by state fee schedules, while clinical operations and health data are subject to state licensing, privacy, and security rules.
Company facts
Key statistics
Year to date +76.5% · Average volume (30d) 867.6K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 11, 2026 | Wells Fargo | Reiterate | Overweight | $40 | |
| Aug 10, 2026 | Truist Financial | Target | $37 | $42 | |
| Aug 10, 2026 | Deutsche Bank | Reiterate | Buy | $32 | $41 |
| Aug 10, 2026 | Mizuho Securities | Target | $40 | ||
| Jul 14, 2026 | Truist Financial | Target | $29 | $37 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | $0.42 | $0.52 | +23.3% | $591.7M | $606.0M | +2.4% | +11.53% |
| May 7, 2026Q1 FY26 | $0.35 | $0.40 | +14.3% | $553.5M | $569.6M | +2.9% | +2.37% |
| Jan 28, 2026Q4 FY25 | $0.23 | $0.28 | +23.5% | $532.1M | $539.1M | +1.3% | +0.56% |
| Nov 6, 2025Q3 FY25 | $0.37 | $0.39 | +5.4% | $532.0M | $572.8M | +7.7% | +3.37% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $500.8M | $550.8M | $572.8M | $539.1M | $569.6M | $606.0M | |
| Gross profit | $143.7M | $161.5M | $167.3M | $140.7M | $170.5M | $192.1M | |
| Operating income | $80.3M | $89.5M | $94.5M | $69.7M | $95.6M | $115.1M | |
| Net income | $38.9M | $44.6M | $48.3M | $34.7M | $50.5M | $65.3M | |
| Diluted EPS | $0.31 | $0.34 | $0.37 | $0.28 | $0.39 | $0.50 | |
| Gross margin | 28.7% | 29.3% | 29.2% | 26.1% | 29.9% | 31.7% | |
| Operating margin | 16.0% | 16.3% | 16.5% | 12.9% | 16.8% | 19.0% |
Fiscal years (4-quarter sums)FY23 $1.84B · FY24 $1.90B · FY25 $2.16B
Balance sheet, Jun 30, 2026Cash & short-term investments $158.0M · Total debt $2.14B · Total assets $3.01B · Shareholders' equity $477.1M
Dividends
To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 20, 2026 | Aug 20 | Aug 28 | $0.0625 | |
| May 19, 2026 | May 19 | Jun 9 | $0.0625 | |
| Mar 12, 2026 | Mar 12 | Mar 19 | $0.0625 | |
| Dec 2, 2025 | Dec 2 | Dec 9 | $0.0625 | |
| Aug 21, 2025 | Aug 21 | Aug 28 | $0.0625 | |
| May 20, 2025 | May 20 | May 29 | $0.0625 | |
| Mar 18, 2025 | Mar 18 | Apr 1 | $0.0625 | |
| Nov 13, 2024 | Nov 13 | Nov 22 | $0.0625 |
Ownership
Shares outstanding 127.96M · Float 114.50M · 89.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Select Medical Corporation | 104.09M | 81.70% | 13G | Sep 5, 2024 |
| BlackRock, Inc. | 17.75M | 13.87% | 13F | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 17.72M | 13.84% | 13F | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 6.82M | 5.33% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 5.13M | 4.01% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 3, 2026 | Robert A. Ortenzio | director | −130,000 | $31.84 |
| Jul 1, 2026 | Robert A. Ortenzio | director | −130,000 | $30.50 |
| Jun 1, 2026 | Robert A. Ortenzio | director | −130,000 | $25.00 |
| May 8, 2026 | Robert A. Ortenzio | director | −130,000 | $25.00 |
Peers
- HCA Healthcare
Urgent care and occupational medicine overlap via CareNow
- UnitedHealth Group
Overlap in work injury care, employer exams, and testing
- CorVel
Workers' comp claims, clinical, network, and virtual-care overlap
- CVS Health
Retail clinics overlap in employer physicals and screenings
- Labcorp
Employer testing network overlapping drug screens and wellness
- Quest Diagnostics
Employer testing overlap in drug screening and occupational labs
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Concentra | $34.51 | +0.74% | $4.38B | 22.2 | 20.0 | 1.9 | +10.0% |
| HCA Healthcare | $417.82 | −0.00% | $90.46B | 14.0 | 13.6 | 1.2 | +8.7% |
| UnitedHealth Group | $392.50 | −0.12% | $356.86B | 25.3 | 18.4 | 0.8 | +0.4% |
| CorVel | $69.24 | −0.01% | $3.53B | 30.8 | — | 3.6 | +10.7% |
| CVS Health | $93.07 | +0.02% | $118.74B | 24.6 | 11.5 | 0.3 | +7.3% |
| Labcorp | $333.00 | −0.68% | $27.48B | 27.7 | 17.7 | 1.9 | +5.8% |
| Quest Diagnostics | $244.50 | +0.69% | $26.79B | 25.8 | 21.2 | 2.3 | +10.2% |
| Median | 25.5 | 17.7 | 1.5 | +8.0% |